Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus.

Publication Date

2015

Journal Title

J Bone Miner Res

Abstract

This work provides a systematic review of the literature from January 2003 to April 2014 pertaining to the incidence, pathophysiology, diagnosis, and treatment of osteonecrosis of the jaw (ONJ), and offers recommendations for its management based on multidisciplinary international consensus. ONJ is associated with oncology-dose parenteral antiresorptive therapy of bisphosphonates (BP) and denosumab (Dmab). The incidence of ONJ is greatest in the oncology patient population (1% to 15%), where high doses of these medications are used at frequent intervals. In the osteoporosis patient population, the incidence of ONJ is estimated at 0.001% to 0.01%, marginally higher than the incidence in the general population (

Volume Number

30

Issue Number

1

Pages

3-23

Document Type

Article

Status

Faculty

Facility

School of Medicine

Primary Department

Dental Medicine

PMID

25414052

DOI

10.1002/jbmr.2405

For the public and Northwell Health campuses

Share

COinS